OncoMatch/Clinical Trials/NCT05779917
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Is NCT05779917 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CAR-T cells for pancreas cancer.
Treatment: CAR-T cells — The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: MSLN overexpression
advanced cancer that expresses Mesothelin protein
Demographics
Prior therapy
Cannot have received: gene therapy
Lab requirements
Blood counts
adequate blood function
Kidney function
adequate kidney function
Liver function
adequate liver function
Cardiac function
adequate heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05779917 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require MSLN?
Yes, MSLN overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages